Hold Rating Maintained on Centene Amid Improving Outlook but Persistent Valuation and Execution Risks

In a report released on February 6, Erin Wright from Morgan Stanley maintained a Hold rating on Centene, with a price target of $38.00.

Erin Wright has given his Hold rating due to a combination of factors including a cleaner quarter and a 2026 outlook that modestly exceeds prior expectations, but not enough to materially change the risk-reward profile. The company’s updated earnings and medical loss ratio guidance suggest improving visibility and that some recent concerns, particularly around Medicare Advantage prescription drug exposure seen at peers, may be more company-specific than sector-wide.

At the same time, valuation remains only moderately attractive, with Centene trading slightly below its own historical multiples and at a notable discount to the broader market, reflecting persistent worries about Medicaid rate-acuity misalignment and commercial margin pressure. Mixed medical loss ratio performance across business lines and the need for more clarity on utilization trends, rate resets, and out-of-period items leave key execution risks intact, supporting a neutral stance rather than a more constructive rating.

In another report released yesterday, TipRanks – xAI also reiterated a Hold rating on the stock with a $37.00 price target.

CNC’s price has also changed dramatically for the past six months – from $25.210 to $38.460, which is a 52.56% increase.